期刊
BIOLOGICAL PSYCHIATRY
卷 76, 期 7, 页码 527-535出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2013.12.005
关键词
Antidepressant medication; biomarker; depression; psychotherapy; subcallosal cingulate; superior temporal sulcus
资金
- National Institutes of Health [R01 MH073719, T32 GM08695, K23 MH086690, K23 MH077869]
- AstraZeneca
- Bristol-Myers Squibb
- Evotec
- Forest
- GlaxoSmithKline
- Novartis
- Ono Pharmaceuticals
- Pfizer
- Shire
- Takeda
- Transcept
- St. Jude Medical Neuromodulation
- Otsuka
- St. Jude Medical, Inc.
- Cervel Neurotech
Background: Treatment approaches for major depressive disorder (MDD) result in approximately one third of patients achieving remission after a first treatment. Added treatment generally improves remission rates, but approximately one third of all patients fail to respond after several treatments (sequential monotherapies or combined treatment). A pretreatment biomarker could help identify these patients. Overactivity of the subcallosal cingulate has been associated with failure of response to treatment in MDD, and it is a potential candidate for such a biomarker. Methods: Investigators enrolled 82 patients with MDD currently not receiving treatment in a two-phase treatment study. Patients underwent a fluorodeoxyglucose positron emission tomography scan. After scanning, patients were randomly assigned to 12 weeks of treatment with either escitalopram or cognitive-behavioral therapy (CBT). Patients not achieving remission after 12 weeks of initial treatment were treated with an additional 12 weeks of escitalopram plus CBT. Subcallosal cingulate metabolism was compared between patients who failed to achieve a response and patients who achieved remission as a result of either phase one or phase two treatment. This analysis was followed by a whole-brain analysis making the same comparison. Results: After two phases of treatment (24 weeks), 36 patients were identified as remitters, 6 patients were responders, and 9 patients were nonresponders. Subcallosal cingulate metabolism was significantly higher in nonresponders than remitters. In the follow-up whole-brain analysis, increased superior temporal sulcus activity was also associated with nonresponse to two treatments. Conclusions: Patients with MDD who fail to achieve remission as a result of CBT or escitalopram, either alone or in combination, have a distinct brain metabolic pattern compared with patients who achieve remission as a result of CBT, escitalopram, or their combination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据